摘要
目的采取贝伐单抗联合紫杉醇和顺铂治疗晚期宫颈癌,观察临床治疗效果及不良反应情况,探讨内在机制。方法将在我院就诊治疗的38例晚期宫颈癌患者随机分为对照组和治疗组,每组有19例。对照组的患者在第1 d先静滴多西紫杉醇30 mg/m2,在第2 d再静滴顺铂50 mg/m2。治疗组的患者则是先静滴贝伐单抗5 mg/kg,然后再采取对照组的化疗方案。两组患者均要连续治疗3个疗程,共计6周。治疗后观察两组患者的临床治疗效果及不良反应情况。结果治疗组患者的临床有效率、生存质量改善率高于对照组,差异有统计学意义(P<0.05)。治疗组患者出现的消化道反应、骨髓抑制及肾功损害等不良反应与对照组患者对比相对较轻,差异有统计学意义(P<0.05)。结论贝伐单抗联合紫杉醇和顺铂治疗晚期宫颈癌临床效果较好,患者的生存质量得到改善。
Objective To investigate the clinical efficacy of bevacizumab combined paclitaxel and cisplatin treatment cervical cancer in late stage.MethodsPatients were divided into treatment group and control group. The control group were treated with paclitaxel 30 mg/m2 by intravenous drip on the first day and cisplatin 50 mg/m2 by intravenous drip on the second day. The treatment group were treated with bevacizumab 5 mg/kg before giving the control group chemotherapy drugs. Two group were treated for six weeks. We observed curative effect and adverse reactions after treatment. ResultsThe effective rate and life quality improvement rate of treatment group was significantly higher than control group（P〈0.05）. The adverse reactions of treatment group was less than control group in bone marrow inhibition and blood cels reduction（P〈0.05）.ConclusionBevacizumab combined paclitaxel and cisplatin can improve the patients life quality,have the good clinical efficacy and slightly adverse reactions,worth clinical application.
出处
《中国卫生标准管理》
2016年第15期108-109,共2页
China Health Standard Management
关键词
贝伐单抗
紫杉醇
顺铂
宫颈癌
Bevacizumab
Paclitaxel
Cisplatin
Cervical cancer
